- Home
- TRIB vs BTAI Comparison
TRIB vs BTAI Comparison
Compare TRIB & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- BTAI
- Stock Information
- Founded
- TRIB 1992
- BTAI 2017
- Country
- TRIB Ireland
- BTAI United States
- Employees
- TRIB N/A
- BTAI N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- BTAI Health Care
- Exchange
- TRIB Nasdaq
- BTAI Nasdaq
- Market Cap
- TRIB 24.0M
- BTAI 28.7M
- IPO Year
- TRIB N/A
- BTAI 2018
- Fundamental
- Price
- TRIB $0.80
- BTAI $0.34
- Analyst Decision
- TRIB
- BTAI Strong Buy
- Analyst Count
- TRIB 0
- BTAI 4
- Target Price
- TRIB N/A
- BTAI $5.00
- AVG Volume (30 Days)
- TRIB 177.5K
- BTAI 1.0M
- Earning Date
- TRIB 11-15-2024
- BTAI 11-14-2024
- Dividend Yield
- TRIB N/A
- BTAI N/A
- EPS Growth
- TRIB N/A
- BTAI N/A
- EPS
- TRIB N/A
- BTAI N/A
- Revenue
- TRIB $59,126,000.00
- BTAI $2,276,000.00
- Revenue This Year
- TRIB $11.63
- BTAI $164.86
- Revenue Next Year
- TRIB $10.13
- BTAI $69.74
- P/E Ratio
- TRIB N/A
- BTAI N/A
- Revenue Growth
- TRIB N/A
- BTAI 83.25
- 52 Week Low
- TRIB $0.75
- BTAI $0.30
- 52 Week High
- TRIB $3.55
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- TRIB 27.93
- BTAI 34.25
- Support Level
- TRIB $0.75
- BTAI $0.35
- Resistance Level
- TRIB $1.01
- BTAI $0.52
- Average True Range (ATR)
- TRIB 0.11
- BTAI 0.06
- MACD
- TRIB 0.00
- BTAI -0.00
- Stochastic Oscillator
- TRIB 11.63
- BTAI 15.92
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.